Boston, July 30, 2025 (GLOBE NEWSWIRE) — According to the latest study from BCC Research, the “Human Microbiome-based Drugs and Diagnostics: Global Markets” is expected to grow from $393.4 million in 2025 to $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.
This report analyzes the global market for human microbiome-based drugs and diagnostics, focusing on market trends and segmentation by type, application, end user, and region. Drug delivery methods include oral and rectal routes, while diagnostics are divided into instruments and reagents/kits. Applications cover metabolic, gastrointestinal, infectious diseases and cancer. It also explores emerging technologies, the competitive landscape, and companies’ ESG initiatives, Wellness products and nonstandardized fecal microbiota transplantation procedures are beyond the scope of the report.
This report is particularly relevant today because microbiome-based drugs show great promise in treating infectious diseases, especially when standard treatments fail. As research advances, these drugs are expected to expand into areas like cancer, neurological disorders, immune-related conditions, and metabolic diseases. Growing awareness of the microbiome’s role in health and disease, along with rising demand for diagnostics that aid in prevention and monitoring, is driving market growth.
The factors driving the market’s growth include:
Growing Evidence of Microbiome-Disease Correlation: Research continues to uncover strong links between microbiome imbalances and diseases like diabetes, cancer, and neurological disorders. This growing understanding is driving demand for microbiome-targeted therapies and diagnostics.
Microbiome-based Diagnostics for Disease Prevention and Monitoring: Microbiome diagnostics are enabling earlier detection and personalized monitoring of diseases through non-invasive tests. These tools support preventive healthcare and are becoming integral to precision medicine.
Drugs and Diagnostics for Skin and Lung Microbiomes: Beyond the gut, the skin and lung microbiomes are emerging as important areas for therapeutic development. Innovations here aim to treat conditions like eczema, asthma, and respiratory infections.
Growing Interest in Direct-to-Consumer (D2C) Microbiome Testing: Consumers are increasingly using at-home microbiome testing kits to gain insights into their health and diet. This trend is expanding the market and encouraging personalized wellness solutions.
Request a sample copy of the global market for human microbiome-based drugs and diagnostics reports.
Report Synopsis
| Report Metric | Details |
| Base year considered | 2024 |